Background Many randomised controlled trials have investigated the eff ect of adjuvant chemotherapy in operable non-small-cell lung cancer. We undertook two comprehensive systematic reviews and meta-analyses to establish the eff ects of adding adjuvant chemotherapy to surgery, or to surgery plus radiotherapy.
Introduction
Around 1·5 million new cases of lung cancer are diagnosed every year, 1 and about 85% of tumours are non-small-cell lung cancer. 2 Although surgery is regarded as the best possible treatment, only 20-25% of tumours are suitable for potentially curative resection. 3 Our previous meta-analyses of individual patient data 4 provided evidence that cisplatin-based chemotherapy after surgery might increase survival (hazard ratio [HR] 0·87, 95% CI 0·74-1·02, p=0·08). With fewer trials and patients, the value of chemotherapy after surgery plus postoperative radiotherapy was less clear in our previous meta-analyses. 4 Meta-analyses [5] [6] [7] [8] [9] [10] showing signifi cant survival benefi ts with adjuvant chemotherapy have included many trials and patients (webappendix p 1). We aimed to assess the eff ects of adjuvant chemotherapy, with or without postoperative radiotherapy, in two new comprehensive meta-analyses of individual patient data. By comparison with our previous meta-analyses, this study was restricted to patients with early stage disease.
Methods

Study design, search strategy, and study selection
Before data collection, two protocols were developed: one for the meta-analysis of chemotherapy plus surgery and the other for the meta-analysis of chemotherapy plus surgery and radiotherapy. To be included, trials had to be randomised, not confounded by additional therapeutic diff erences between the two groups, and have started randomisation on or after Jan 1, 1965 . Trials should have aimed to include patients who had undergone a potentially curative resection and not received previous chemotherapy. For the fi rst meta-analysis, trials should have compared surgery plus adjuvant chemotherapy versus surgery alone. For the second, trials should have compared surgery plus adjuvant radiotherapy and chemotherapy versus surgery plus adjuvant radiotherapy. We excluded trials using long-term alkylating agents for more than 1 year, because these agents are no longer used to treat non-small-cell lung cancer and are harmful. 4 To limit publication bias, we included published and unpublished trials with no restriction by language.
See Online for webappendix Searches of Medline and CancerLit (with an amended version of the Cochrane Collaboration optimal search strategy 11 ) and trial registers, with additional MESH and free text terms for non-small-cell lung cancer and chemotherapy, were supplemented by hand searches of conference proceedings and reference lists of trial publications and review articles. Our collaborators were asked whether they knew of additional trials. Initial searches were undertaken in 2003 and were regularly updated until September, 2009.
Data collection
For the 15 trials included in our previous meta-analysis undertaken in 1995, we sought only updated follow-up. For new trials, we gathered data for age, sex, extent of resection, pathological tumour stage, histology, performance status, treatment group, date of randomisation, recurrence, survival, and follow-up for all patients randomly assigned.
We used standard checks to identify missing data, assess data validity, and consistency. We verifi ed the amount of missing data, checked the order of dates, and assessed data validity and consistency. To assess randomisation integrity, we checked patterns of treatment allocation and balance of baseline characteristics by treatment group. Follow-up of surviving patients was checked to ensure that it was balanced by treatment group and was up-to-date. Any queries were resolved and the fi nal database verifi ed by each trial investigator or statistician
Defi nition of outcome measures
The primary outcome of overall survival was defi ned as the time from randomisation until death by any cause. Living patients were censored on the date of last followup. Recurrence-free survival, a secondary outcome, was defi ned as the time from randomisation until fi rst recurrence or death by any cause. Patients alive without disease were censored on the date of last follow-up. To avoid bias from under-reporting of subsequent events, time to locoregional recurrence was defi ned as the time from randomisation until fi rst locoregional recurrence, and patients with previous distant recurrences were censored at the time of distant recurrence. Similarly, for time to distant recurrence, patients with previous locoregional recurrences were censored on that date.
Statistical analysis
Unless otherwise stated, all analyses were prespecifi ed in the protocols, and undertaken on an intention-to-treat basis. For every outcome, we used the log-rank expected number of events and variance to calculate individual trial HRs, which were pooled across trials with the fi xedeff ect model. Survival is also presented with simple (non-stratifi ed) Kaplan-Meier curves. We calculated the median follow-up for all patients with the reverse Kaplan-Meier method.
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For survival, to explore any eff ect of trial and patient characteristics on the eff ect of chemotherapy, pooled HRs were calculated for every prespecifi ed trial group or patient subgroup. We used χ² tests for interaction to investigate diff erences in the treatment eff ect across trial groups. To investigate diff erences in the treatment eff ect across patient subgroups, we undertook Cox regressions including the relevant treatment by subgroup interaction term within trials and the interaction coeffi cients (HRs) pooled across trials. χ² tests and the I² statistic were used to assess heterogeneity in the treatment eff ect or patient subgroup interactions across trials.
We calculated absolute diff erences in overall survival at 5 years using overall HRs and survival in the control group. If a diff erence in eff ect by trial group or patient subgroup was identifi ed, we used HRs and control group survival for the relevant groups to calculate absolute diff erences; otherwise the overall HR was used.
Since two trials compared two chemotherapy regimens with one control group, 13, 14 we compared every treatment group with the control group and analysed as separate trial comparisons in diff erent chemotherapy categories. However, to avoid double-counting the control groups in the overall and subgroup analyses, the treatment groups were combined and compared with the relevant control group. For other trials that belonged in diff erent chemotherapy categories 15 or diff erent meta-analyses, [16] [17] [18] or both, 19, 20 we compared relevant patients from the treatment group with the corresponding patients in the control group, and analysed them as separate trial comparisons. This method of analysis provides a greater number of trial comparisons than there are trials.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or 
S alone better writing of the report. The corresponding authors had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
For the meta-analysis of surgery and chemotherapy versus surgery, we identifi ed 35 eligible trials, of which 26 were included: nine from the previous meta-analysis done in 1995, and 17 additional trials. Nine trials could not be included because: data were not available for three published [21] [22] [23] and two small unpublished trials (NCCTG 852451, EORTC 08922), adequate contact with the investigators could not be established for two trials, 24, 25 and two trials have only recently been presented. 26, 27 Therefore, data from 26 published trials [13] [14] [15] [16] [17] [18] [19] [20] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] were included, allowing 34 trial comparisons (table 1) .
Platinum-based chemotherapy without a combination of tegafur and uracil or tegafur alone was used in 18 trial comparisons, and with tegafur and uracil or tegafur in eight (table 1) . In all but one trial, 44 cisplatin was the platinum agent. Tegafur and uracil or tegafur alone was used in combination with other agents in one trial comparison and alone in seven (table 1) . Data for histology and stage were provided for all 34 trial comparisons, age and sex for 33, and performance status for 24 (webappendix p 2). Patients were mostly men with a median age of 61 years (range 18-84). They tended to have good performance status and tumours that were predominantly stage I-II adenocarcinomas or squamous cell carcinomas (webappendix p 2). The few patients with stage IIIB and IV tumours included-eg, because of misclassifi cation at diagnosis-were combined with stage IIIA patients for analysis; this group is subsequently referred to as stage III. The median follow-up was 5·5 years (IQR 4·4-6·6).
Survival results for the fi rst meta-analysis were based on 34 trial comparisons and 8447 patients (3323 deaths), representing 92% of patients who were randomly assigned. The results show a benefi t of chemotherapy (HR 0·86, 95% CI 0·81-0·92, p<0·0001; fi gure 1), with minimum heterogeneity (p=0·40, I²=4%). This fi nding represents an absolute improvement of 4% (95% CI 3-6) at 5 years, increasing survival from 60% to 64% (fi gure 2). We noted a diff erence in eff ect by chemotherapy category (interaction p=0·06, fi gure 1), largely driven by the result of the OLCSG1b trial 20 that alone constituted the chemotherapy category for tegafur and uracil or tegafur plus other agent. A sensitivity analysis excluding this trial did not suggest that this drug regimen aff ects the eff ect of chemotherapy (data not shown; interaction p=0·30).
In view of the diff erences in the types of chemotherapy used over time and by geographical region, we grouped trial comparisons by these characteristics for exploratory analyses. We noted no clear evidence of a diff erence in the eff ect between trial comparisons included in the 1995 meta-analysis, and those included since this time (interaction p=0·76), by accrual decade (interaction p=0·61), or by geographical region (North America, Europe, Asia; interaction p=0·25; data not shown). 20 (data not shown; interaction p=0·07).
We recorded no signifi cant evidence (p≥0·10) that any patient subgroup defi ned by age, sex, histology, performance status, or stage benefi ted more or less from chemotherapy (webappendix p 4). However, because of the geographical diff erences in the types of patients and chemotherapy used, we undertook exploratory subgroup analyses separately for trial comparisons using platinum, without tegafur and uracil or tegafur, and those using these drugs. Stage I disease was also split into IA and IB for all but four trials, 15, 29, 33, 41 which had to be excluded since this information was not available.
For the platinum without tegafur and uracil or tegafur alone group, although there was no evidence of diff erence in the eff ect of chemotherapy between patients with good and poor performance status (interaction p=0·30; fi gure 3), we noted an increasing relative eff ect of chemotherapy with improving performance status (trend p=0·002; fi gure 3), which was consistent across trials (data not shown; p=0·32). However, a few patients had a poor performance status (fi gure 3). The relative eff ect of chemotherapy did not diff er signifi cantly by other patient subgroups, including stage (trend p=0·13; fi gure 3). Therefore, application of the overall hazard ratio to survival in the control group by stage suggests absolute improvements in 5-year survival of 3% (95% CI 2-5) for stage IA (from 70% to 73%), 5% (2-7) for stage IB (from 55% to 60%), 5% (3-8) for stage II (from 40% to 45%), and 5% (3-8) for stage III disease (from 30% to 35%). The suggested survival benefi t of 3% for stage IA and the HR of 1·19 (95% CI 0·84-1·68) for that subgroup seemed to be contradictory. However, data are scarce for this group of patients, the CIs are very wide, and the result is not signifi cant (p=0·33).
In the tegafur and uracil or tegafur alone group, we noted no clear diff erence in the eff ect of chemotherapy between patients with good or poor performance status (interaction p=0·49; fi gure 3), but did record a suggestion of an increasing relative eff ect of chemotherapy with worsening performance status (trend p=0·02; fi gure 3). This trend varies substantially across trials (data not shown; p=0·01), and few patients had a poor performance status. We noted no signifi cant diff erence in the relative eff ect of chemotherapy by age, sex, histology, or stage, and application of the overall HR gave absolute improvements in 5-year survival of 2% (95% CI 1-3) for stage IA (from 80% to 82%), 3% (1-4) for stage IB (from 75% to 78%), 5% (2-7) for stage II (from 45% to 50%), and 5% (3-8) for stage III disease (from 25% to 30%).
Data for recurrence-free survival were available for 18 trial comparisons (2519 events; 5379 patients) and data for locoregional (936 events; 5226 patients) and distant recurrence (1267 events; 5224 patients) for 16 trial comparisons, mostly from newer trials of platinum-based chemotherapy without tegafur and uracil or tegafur alone. Results for recurrence-free survival (HR 0·83, 95% CI 0·77-0·90, p<0·0001), time to locoregional recurrence (0·75, 0·66-0·85, p<0·0001), and time to distant recurrence (0·80, 0·72-0·89, p=0·0007) all signifi cantly favoured chemotherapy. Exclusion of the four trial comparisons that included tegafur and uracil or tegafur alone 14, 34, 35, 38 showed similar results (data not shown).
For the second meta-analysis of surgery plus radiotherapy and chemotherapy versus surgery plus radiotherapy, we identifi ed 15 eligible trials, of which 12 were included: six from the previous meta-analysis in 1995 and six additional trials. Three could not be included because: data were not available for one trial, 22 and adequate contact with investigators could not be made for two trials. 46, 47 Therefore, nine published [16] [17] [18] [19] [20] [48] [49] [50] [51] and three unpublished (EORTC 08861, MDA DM 87045, FLCSG3) trials were included, allowing 13 trial comparisons (table 2) . In nine trial comparisons chemotherapy was given before radiotherapy, and in four it was given concurrently with radiotherapy (table 2) . Platinum and a vinca alkaloid or etoposide was used in ten trial comparisons, platinum and tegafur and uracil or tegafur alone in one, and other platinum regimens in two (table 2) . Cisplatin was the sole platinum agent. Data for age, sex, and histology were supplied for all trial comparisons, stage and extent of resection for 12, and performance status for 11 (webappendix p 2). On the basis of these data, patients were mostly men, with good performance status, a median age of 59 years (range 27-81), and stage III, squamous carcinomas (webappendix p 2). The few patients with stage IV tumours were combined with stage III patients for analyses, and referred to as stage III. The median follow-up was 6·4 years (IQR 4·6-8·3).
Survival analyses were based on 13 trial comparisons and 2660 patients (1909 deaths), representing 86% of patients who were randomly assigned. The results showed a clear benefi t of chemotherapy (HR 0·88, 95% CI 0·81-0·97, p=0·009; fi gure 4), with little heterogeneity (p=0·95, I²=0%). This fi nding represents an absolute benefi t of 4% (95% CI 1-8) at 5 years, increasing survival from 29% to 33% (fi gure 2). We recorded no evidence of a diff erential eff ect by chemotherapy category (interaction p=0·45; fi gure 4) or the extent of resection achieved (interaction p=0·54; data not shown), although few patients had incomplete resections. Furthermore, an exploratory analysis suggests that the timing of chemotherapy in relation to radiotherapy is unimportant (chemotherapy before radiotherapy, concomitant chemoradiotherapy; interaction p=0·28; data not shown).
The relative eff ect of chemotherapy did not diff er signifi cantly by age, sex, histology, performance status, or stage (webappendix p 6). Data for recurrence-free survival, and locoregional and distant recurrence, were available for eight trial comparisons (2247 patients).
Results for recurrence-free survival (1673 events, 2247 patients; HR 0·85, 95% CI 0·77-0·93, p=0·0006), time to locoregional recurrence (533 events; 0·79, 0·67-0·94, p=0·008), and time to distant recurrence (806 events; 0·75, 0·66-0·87, p<0·0001) all showed a signifi cant benefi t of chemotherapy.
Discussion
Our results show a benefi t of adjuvant chemotherapy after surgery, which has been already shown in some large trials but not in others (eg, ALPI 15 and CALGB 9633 43 ). They also show a benefi t of chemotherapy in the presence of postoperative radiotherapy. The absolute survival improvements of 4% at 5 years are fairly modest, but might result in 10 000 more patients alive at 5 years. 3 The results of the two meta-analyses are based on data from 47 comparisons in 33 trials and 11 107 patients with non-small-cell lung cancer, which is more than three times that available in 1995. 4 In these meta-analyses, we have an opportunity to bring together most trials undertaken during the past few decades, and to assess the eff ectiveness of adjuvant chemotherapy in patients with non-small-cell lung cancer worldwide.
Although we noted no signifi cant diff erence in eff ect between chemotherapy categories in the fi rst metaanalysis, results for the trials that used older vinca alkaloids (vinblastine, vindesine, vincristine), etoposide, or other platinum combinations were somewhat uncertain, whereas trials using a combination of platinum and vinorelbine provided slightly more reliable evidence of benefi t to inform present clinical practice (fi gures 1 and 4). The results for chemotherapy with tegafur and uracil or tegafur alone are similar to those for platinum-based regimens. However, results come largely from older studies in Asian populations, which are increasingly showing diff erences in their response to treatment, 52 and so cannot be extrapolated to modern practice in non-Asian patients. A trial of tegafur and uracil or tegafur alone in patients with stage IA, adenocarcinoma from non-Asian countries would be benefi cial in this context. Results of an ongoing trial might establish the relative merits of carboplatinpaclitaxel and tegafur and uracil in Asian patients. 53 Guidelines from Cancer Care Ontario and American Society of Clinical Oncology (ASCO) [17] [18] [19] 42, 54 recommend that adjuvant cisplatin-based chemotherapy is given to patients with stage II and IIIA non-small-cell lung cancer. These guidelines state that evidence is insuffi cient to make recommendations for patients with stage IA The ASCO guidelines also state that none of the studies reviewed showed a signifi cant benefi t of adjuvant chemotherapy in patients with stage IB tumours. By contrast, our estimate of the eff ect of platinum-based chemotherapy in patients with stage IB tumours is based on a substantial number of events and is similar to estimates for patients with stage II and III tumours (fi gure 3). Since we did not collect data for tumour size, patients with larger stage IB tumours, who would be classed as stage II in the 7th edition of the TNM staging system 55 and might achieve a greater benefi t from chemotherapy, 44 are potentially included. In the absence of comorbidities and contraindications to chemotherapy, adjuvant platinum-based chemotherapy should be considered for patients at high risk of recurrenceie, those with stage IB, II, or III disease. Whether cisplatin-based chemotherapy should be used in patients with stage IA disease remains uncertain, since the scarcity of data did not allow us to distinguish reliably between a benefi t, a detriment, or no eff ect.
Most patients had good performance status and the benefi t was clear in this group. A small increasing eff ect of platinum-based chemotherapy with better performance status was also apparent in this and another meta-analysis, 10 but was not confi rmed in trials using tegafur and uracil or tegafur alone or those that included postoperative radiotherapy. Nevertheless, these results could suggest cautious use of platinum-based chemotherapy in less fi t patients. Despite the amount of data collected, some of the subgroup analyses lacked power.
The benefi ts of adjuvant chemotherapy have been reported to be attenuated in long-term results;
56,57 however, we do not have much data beyond 5 years. The potential benefi t of chemotherapy should always be balanced with possible toxic eff ects for the individual patient. We were unable to assess toxic eff ects of treatment in this study. Moreover, extrapolation of the results to patients with comorbidities is uncertain because most of the patients included in these meta-analyses had mild or no comorbidities.
Addition of chemotherapy to surgery and postoperative radiotherapy gave a 4% improvement in 5-year survival from 29% to 33%. This increase does not seem to vary with the timing of chemotherapy in relation to radiotherapy, extent of surgery, or by patient subgroup (table 2, webappendix p 5). The lower survival rates than those in the surgery and chemotherapy meta-analysis are most likely because patients with stage III tumours predominate and the incomplete resection rate is higher (table 2) . A previous meta-analysis 58, 59 has shown that postoperative radiotherapy has a detrimental eff ect on survival, particularly for early stage tumours, but old radiotherapy techniques were used. This meta-analysis was not designed to study the eff ect of postoperative radiotherapy, but has shown that the eff ect of chemotherapy is similar irrespective of what locoregional treatment is used: surgery alone or surgery plus postoperative radiotherapy. Randomised trials are needed to assess whether modern radiotherapy is eff ective as an adjuvant treatment.
